Pediculosis therapy - Piedmont Pharmaceuticals

Drug Profile

Pediculosis therapy - Piedmont Pharmaceuticals

Alternative Names: Full Marks Solution; Head lice therapy - Piedmont Pharmaceuticals; Pediculicide rinse - Piedmont Pharmaceuticals; Resultz Rinse

Latest Information Update: 06 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Piedmont Pharmaceuticals
  • Developer Nycomed Canada; Piedmont Pharmaceuticals; Reckitt Benckiser
  • Class Antiparasitics; Pyrethrins; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pediculosis

Most Recent Events

  • 30 Sep 2011 Nycomed has been acquired by Takeda
  • 29 Oct 2010 SSL International has been acquired by Reckitt Benckiser
  • 09 Aug 2010 Phase III development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top